Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Vorapaxar - wikidoc
APExBIO - Vorapaxar|PAR-1 antagonist,potent and orally active|CAS# 618385-01-6
Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
Vorapaxar - Wikipedia
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™) | SpringerLink
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
Late Breaking Clinical Trials: CORONARY (On-Pump vs. Off-Pump CABG), CPORT (Nonprimary PCI Without Surgical Backup), ASCERT (CABG vs. PCI), and TRAP2-TIMI 50 (Vorapaxar for... | tctmd.com
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
![PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c4d402004bb1cd7f7142aa35447751937911b5ff/2-Figure1-1.png "PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar")
PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar - ScienceDirect
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes | NEJM
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
IJMS | Free Full-Text | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Vorapaxar | Uses, Brand Names, Mechanism Of Action
Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease - Justin T. Morrison, Nicholas Govsyeyev, Connie N. Hess, Marc P. Bonaca, 2022
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction | tctmd.com
